Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00395421 | Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin | PHASE2 | COMPLETED | 114 | — | — | Oct 1, 2006 | Aug 1, 2008 | Jun 10, 2010 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW) |
| Name | Type | Description |
|---|---|---|
| NM283 plus Peg-IFNα-2a | DRUG | 200 mg QD 180 µg QW |
Inclusion Criteria: * Documented clinical history compatible with chronic hepatitis C and compensated liver disease * Has not previously received anti-viral therapy for hepatitis C infection Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patient is pregnant or breastf...